Benzinga
26 Jan 2026, 15:06 UTC · 38w ago
Verdict
Headline leans bearish. We score COGT +1.00 across four claims.
Score contradicts the headline.
Leans bearish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA granted Breakthrough Therapy Designation to Cogent's bezuclastinib in combination with sunitinib for the treatment of Gastrointestinal Stromal Tumors (GIST).
More positive than 99% of claims this week
The PEAK trial showed the bezuclastinib combination achieved a median progression-free survival of 16.5 months versus 9.2 months for sunitinib monotherapy.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 98% of claims this week
The FDA accepted Cogent's NDA for the bezuclastinib combination under the Real-Time Oncology Review (RTOR) program, with full submission expected in April 2026.
More positive than 98% of claims this week
Cogent plans to initiate a Phase 2 trial in mid-2026 for first-line GIST patients with exon 9 mutations, expanding the drug's addressable patient population.
More positive than 81% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Received FDA Breakthrough Therapy Designation and reported positive clinical trial results for stomach cancer treatment.
More negative than 65% of ticker scores this week
Its drug sunitinib was used as the control arm and performed significantly worse than Cogent's combination therapy.
Near neutral — 92% of ticker scores this week are stronger
Mentioned only as a prior treatment provider for trial patients without a direct impact on company performance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
2h ago
−14.8%
Price is moving against the score
$31.24 vs $36.68 close before publication (Jan 23) · not market-adjusted
COGT chart →
